TriSalus Life Sciences Reports 44% Q4 Revenue Growth Driven by TriNav® Infusion System

TriSalus Life Sciences Shows Robust Growth with TriNav® Infusion System

TriSalus Life Sciences® Inc. reveals impressive preliminary financial results for the fourth quarter and full year of 2024, largely fueled by the success of its TriNav® Infusion System. The company records approximately $8.3 million in revenue for Q4 2024, a substantial 44% increase compared to the same period in 2023. This surge is part of a broader upward trend, with total revenue for the entire year hitting around $29.4 million—an impressive 59% growth year-over-year. The TriNav® Infusion System, designed to enhance drug delivery to tumors while minimizing systemic exposure, plays a pivotal role in this growth, highlighting TriSalus's commitment to advancing treatment options in the oncology space.

Looking ahead, TriSalus anticipates continued momentum into 2025, projecting revenue growth to exceed 50%. The company’s optimism is grounded in the increasing adoption of the TriNav® Infusion System among healthcare providers, which reflects a growing recognition of its efficacy in improving patient outcomes in cancer treatment. TriSalus actively engages with clinicians and healthcare institutions to expand its market reach, further solidifying its position within the competitive landscape of medical devices and oncology treatments.

Despite reporting an operating cash flow loss of approximately $5.6 million in Q4 2024, TriSalus demonstrates significant improvement from the $10.8 million loss in the previous quarter. The company aims to achieve positive full-year EBITDA and cash flow by the latter half of 2025, bolstered by an anticipated $10 million influx from an existing debt agreement with OrbiMed. This financial strategy is crucial for supporting ongoing operations and innovation efforts, as TriSalus continues to focus on advancing its product pipeline and enhancing its market presence.

In related developments, TriSalus is set to hold a conference call on March 27, 2025, at 8:00 a.m. ET to discuss these financial results and provide additional business updates. It is important to note that the preliminary results are unaudited and may be subject to revisions, emphasizing the need for stakeholders to consider these figures cautiously.

As TriSalus Life Sciences forges ahead, the company’s focus on innovation and operational efficiency positions it well to navigate the evolving landscape of oncology treatment, ensuring it remains at the forefront of advancements beneficial to patients and healthcare practitioners alike.